Search research articles
Contact Us
Filters
Showing results (111-120 of 123) with videos related to
Page
of 13
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)
|
February 15, 2021
Feasibility and Successful Enrollment in a Proof-of-Concept HIV Prevention Trial of VRC01, a Broadly Neutralizing HIV-1 Monoclonal Antibody
Srilatha Edupuganti, Nyaradzo Mgodi, Shelly T Karuna, et al.
Medrxiv : the Preprint Server for Health Sciences
|
April 10, 2026
Safety and immunogenicity of an HIV envelope trimer immunogen that elicits CD4 binding site neutralizing antibody precursors (HVTN 300)
Stephen Walsh, William O Hahn, Wilton B Williams, et al.
Journal of Clinical Microbiology
|
July 21, 2021
Evaluation of Cell-Based and Surrogate SARS-CoV-2 Neutralization Assays
Anton M Sholukh, Andrew Fiore-Gartland, Emily S Ford, et al.
The Lancet. HIV
|
October 14, 2022
Developing tuberculosis vaccines for people with HIV: consensus statements from an international expert panel
Maurine D Miner, Mark Hatherill, Vidya Mave, et al.
PLOS Global Public Health
|
September 20, 2024
Safety and immunogenicity after a 30-month boost of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120/MF59 vaccine boost (HVTN 100): A phase 1-2 randomized double-blind placebo-controlled trial
Vimla Naicker, Fatima Laher, Linda-Gail Bekker, et al.
Medrxiv : the Preprint Server for Health Sciences
|
June 5, 2026
A phase 1 randomized controlled trial to evaluate the safety and immunogenicity of a HIV monomeric gp120 protein B-cell lineage targeting HIV vaccine in healthy adults
James J Kobie, Wilton B Williams, William O Hahn, et al.
Plos Medicine
|
May 23, 2020
Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials
Zoe Moodie, Stephen R Walsh, Fatima Laher, et al.
Plos Medicine
|
March 19, 2024
Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial
Zoe Moodie, Erica Andersen-Nissen, Nicole Grunenberg, et al.
The Lancet. HIV
|
December 12, 2024
Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trial
Srilatha Edupuganti, Christopher B Hurt, Kathryn E Stephenson, et al.
The Lancet. HIV
|
May 29, 2025
Safety, pharmacokinetics, and neutralisation activity of PGDM1400LS, a V2 specific HIV-1 broadly neutralising antibody, infused intravenously or subcutaneously in people without HIV-1 in the USA (HVTN 140/HPTN 101 part A): a first-in-human, phase 1 randomised trial
Kelly E Seaton, Carmen A Paez, Chenchen Yu, et al.
Page
of 13
Search research articles
Search
Showing results (111-120 of 123) with videos related to
Sort By:
Page
of 13
Journal of Acquired Immune Deficiency Syndromes (1999)
|
February 15, 2021
Feasibility and Successful Enrollment in a Proof-of-Concept HIV Prevention Trial of VRC01, a Broadly Neutralizing HIV-1 Monoclonal Antibody
Srilatha Edupuganti, Nyaradzo Mgodi, Shelly T Karuna, et al.
Medrxiv : the Preprint Server for Health Sciences
|
April 10, 2026
Safety and immunogenicity of an HIV envelope trimer immunogen that elicits CD4 binding site neutralizing antibody precursors (HVTN 300)
Stephen Walsh, William O Hahn, Wilton B Williams, et al.
Journal of Clinical Microbiology
|
July 21, 2021
Evaluation of Cell-Based and Surrogate SARS-CoV-2 Neutralization Assays
Anton M Sholukh, Andrew Fiore-Gartland, Emily S Ford, et al.
The Lancet. HIV
|
October 14, 2022
Developing tuberculosis vaccines for people with HIV: consensus statements from an international expert panel
Maurine D Miner, Mark Hatherill, Vidya Mave, et al.
PLOS Global Public Health
|
September 20, 2024
Safety and immunogenicity after a 30-month boost of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120/MF59 vaccine boost (HVTN 100): A phase 1-2 randomized double-blind placebo-controlled trial
Vimla Naicker, Fatima Laher, Linda-Gail Bekker, et al.
Medrxiv : the Preprint Server for Health Sciences
|
June 5, 2026
A phase 1 randomized controlled trial to evaluate the safety and immunogenicity of a HIV monomeric gp120 protein B-cell lineage targeting HIV vaccine in healthy adults
James J Kobie, Wilton B Williams, William O Hahn, et al.
Plos Medicine
|
May 23, 2020
Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials
Zoe Moodie, Stephen R Walsh, Fatima Laher, et al.
Plos Medicine
|
March 19, 2024
Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial
Zoe Moodie, Erica Andersen-Nissen, Nicole Grunenberg, et al.
The Lancet. HIV
|
December 12, 2024
Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trial
Srilatha Edupuganti, Christopher B Hurt, Kathryn E Stephenson, et al.
The Lancet. HIV
|
May 29, 2025
Safety, pharmacokinetics, and neutralisation activity of PGDM1400LS, a V2 specific HIV-1 broadly neutralising antibody, infused intravenously or subcutaneously in people without HIV-1 in the USA (HVTN 140/HPTN 101 part A): a first-in-human, phase 1 randomised trial
Kelly E Seaton, Carmen A Paez, Chenchen Yu, et al.
Page
of 13